This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Vries, E. G. E. Articles by Vellenga, E. Search for Related Content PubMed PubMed Citation Articles by de Vries, E. G. E. Articles by Vellenga, E.

A Double-Blind Placebo-controlled Study with Granulocyte-Macrophage Colony-stimulating Factor during Chemotherapy for Ovarian Carcinoma

Division of Medical Oncology, Department of Internal Medicine [E. G. E. d. V., B. B., P. H. B. W., N. H. M.], Departments of Oncologic Gynaecology [J. G. A.] and Hematology [E. V.], University Hospital Groningen, 9713 EZ Groningen, and The Netherlands, and Departments of Clinical Research, Sandoz, Ltd., Basle, [A. C. S.] Switzerland

In a placebo-controlled double-blind dose-finding trial, 15 patients with ovarian cancer stage III or IV received daily s.c. 1.5, 3, or 6 µg/kg recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). At each dose step three patients received recombinant human GM-CSF, and two received placebo. Chemotherapy comprised 6 cycles of carboplatin, 300 mg/m², and cyclophosphamide, 750 mg/m², by i.v. bolus on day 1 every 4 weeks. GM-CSF, given on days 6–12 on an outpatient basis, raised the mean leukocyte count on days 7, 10, and 15 and the mean neutrophil count on days 7 and 10 at all dose levels as compared with the control group. Neutrophil counts of less than 0.5 x 10⁹/liter occurred in 20 of 22 cycles in the control group and in 5 of 17 cycles at the 6-µg/kg/day GM-CSF dose level (P < 0.0005). In comparison with the control group, the mean eosinophil count was higher on days 10 and 15 at all GM-CSF doses, as was the mean monocyte count on day 15. The mean platelet count was raised at the 3- and 6-µg GM-CSF doses on days 15 and 22. Chemotherapy dose reduction or post-ponement due to myelotoxicity occurred in 9 of 28 cycles in the placebo groups versus 5 of 44 cycles in the GM-CSF group (not significant). Local skin infiltrates at the GM-CSF injection sites occurred in 8/9 patients, leading to premature removal of two patients from the study. Capillary leakage of ¹³¹I-albumin was increased in all patients 5 days after the first chemotherapy course but was not significantly affected by 4 days of GM-CSF treatment. Tumor necrosis factor and C-reactive protein serum levels increased during GM-CSF administration at the 6-µg dose level, but interleukin 6 serum levels were not affected.

We conclude that a dose of 3 and 6 µg/kg/day GM-CSF reduces the severity of neutropenia and thrombocytopenia after carboplatin-cyclophosphamide. This GM-CSF dose does not induce additional capillary leakage.

¹ To whom requests for reprints should be addressed, at Division of Medical Oncology, Department of Internal Medicine, University Hospital, Oostersingel 59, 9713 EZ Groningen, The Netherlands.

² Fellow of the Royal Netherlands Academy of Arts and Sciences.

Received 7/ 6/90. Accepted 10/15/90.

This article has been cited by other articles:

				L. Sung, P. C. Nathan, S. M.H. Alibhai, G. A. Tomlinson, and J. Beyene Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection Ann Intern Med, September 18, 2007; 147(6): 400 - 411. [Abstract] [Full Text] [PDF]

				S. Esnault, Z.-J. Shen, E. Whitesel, and J. S. Malter The Peptidyl-Prolyl Isomerase Pin1 Regulates Granulocyte-Macrophage Colony-Stimulating Factor mRNA Stability in T Lymphocytes J. Immunol., November 15, 2006; 177(10): 6999 - 7006. [Abstract] [Full Text] [PDF]

				A. Kaplan, S. Kaplan, K. F. Marcoe, L. R. Sauvage, and W. P. Hammond The Effect of Hematopoietic Growth Factors on Platelet Aggregability Clinical and Applied Thrombosis/Hemostasis, October 1, 1998; 4(4): 238 - 242. [Abstract] [PDF]